InDex Pharmaceuticals Holding AB (publ) year-end report 2019
(WorldNews Sweden)

Cobitolimod`s outstanding combination of efficacy and safety confirmed in in-depth analysis `The robustness and consistency of the CONDUCT results support our strategy to move cobitolimod forward in development and our phase III preparations are continuing according to plan,` says Peter Zerhouni, CEO of InDex Pharmaceuticals. Period October - December 2019 Net sales amounted to SEK 0.0 (0.0) million Operating loss amounted to SEK -25.6 (-22.3) million Result after tax amounted to SEK -25.6 (-22.3) million, corresponding to SEK -0.29 per share (-0.33) before and after dilution Cash flow from operating activities amounted to SEK -34.2 (-20.6) million Period January - December 2019 Net sales...